The risks of ischemic and hemorrhagicstroke and poor neurological outcomes after stroke are increased in people with type 2 diabetes. Explore how to manage the hyperacute stroke stage and CV disease prevention.
STEP-HFpEF trial findings indicate that weekly semaglutide improves heart failure symptoms, physical limitations, and body weight in people with obesity-related heart failure and type 2 diabetes.
The Improving Diabetes Steering Committee outlines the place, value, and advantages of SGLT2 inhibitors in the treatment of type 2 diabetes. With user-friendly tools to support their use.
This UK consensus guideline provides a practical approach to the assessment and management of type 2 diabetes and associated complications in children and young people.
Our tailored content service will keep you up to date…
Receive newsletters curated for the busy specialist by our expert editorial team
Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.
Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.
Rapidly progressive insulin-dependent diabetes in the absence of islet autoantibodies developed 2 years after starting treatment with the immune checkpoint inhibitor nivolumab.
HC-HB is a rare movement disorder that can occur in patients with poorly controlled diabetes and hyperglycemia without ketoacidosis. The mainstay of treatment is prompt correction of hyperglycemia.
A patient with small-cell lung cancer developed type 1 diabetes many weeks after receiving serplulimab, highlighting the need for continued monitoring of blood glucose levels and early signs and symptoms of diabetes.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
Type 2 DiabetesDiabetes and Cardiovascular Disease (D Bruemmer, Section Editor)
Type 2 diabetes (T2D) is a major health care problem in the US, affecting approximately 37 million Americans or ~ 10% of the adult population, and for every person with T2D, there ~ 2 individuals with prediabetes [ 1 ]. Cardiovascular disease (CVD) …
Type 2 diabetes mellitus (T2DM) is a global health concern, and its prevalence has been steadily increasing over the years [ 1 ]. The International Diabetes Federation (IDF) estimated that approximately 537 million adults (ages 20–79) were living …
One of the most common diseases in the modern era, diabetes mellitus (DM), is caused by a variety of factors, including inherited traits and environmental changes [ 1 ]. The prevalence of this chronic metabolic illness is rising as a result of the …
The high worldwide prevalence of non-communicable metabolic diseases, such as type 2 diabetes (T2D), obesity, hypertension, and dyslipidaemias, persists as a current challenge for public health [ 1 , 2 ]. These diseases remain one of the leading …
Stay up to date with the rapidly changing CGM landscape. Learn how to implement and integrate CGM into diabetes management to improve patient care and outcomes.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Over recent decades, the prevalence of obesity has increased dramatically, reaching pandemic levels worldwide, there being over 1.9 billion adults with overweight or obesity in 2016 [ 1 ]. Overweight and obesity are characterised by an excessive …
Multiple daily injection insulin regimen (MDI), also referred to as intensive insulin therapy (IIT), represents the most complex type of insulin regimen used in the management of people with type 2 diabetes (PwT2D). Correspondingly, MDI regimen …
Insulin therapy is a necessary step in achieving optimal glycemic targets in type 1 diabetes (T1DM), but also in most advanced patients with type 2 diabetes (T2DM) when oral antidiabetic agents and non-insulin injectable treatments have failed to …
The International Diabetes Federation (IDF) Atlas reported that in 2021, 537 million people had diabetes globally; of these, type 2 diabetes is estimated to account for over 90% of cases [ 1 , 2 ]. This number is predicted to increase by 46% to 783 …
